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Abstract
Ischemic stroke is a common complication of atrial fibrillation (AF). Currently, oral anticoagulant 
drugs are the most commonly used method of stroke prevention. Left atrial appendage occlusion is 
thought to be the main source of thrombi in patients with AF. Percutaneous left atrial appendage is 
a valuable therapeutic option for selected high-risk patients with AF and contraindications for oral 
anticoagulation therapy. While complete closure of the left atrial appendage is the goal of a device im-
plantation the variable nature of the left atrial appendage anatomy makes this goal difficult to achieve. 
Currently, there are several types of devices available for left atrial appendage occlusion. Since the first 
percutaneous left atrial appendage occlusion in 2002 many studies have investigated both the safety and 
efficacy of this therapy using different closure devices. Still unresolved issues include a lack of data on 
optimal patient selection, risk of complications, and anticoagulant treatment after left atrial appendage 
occlusion. (Cardiol J 2017; 24, 5: 554–562)
Key words: atrial fibrillation, left atrial appendage, thrombus, occlusion,  
contraindications to anticoagulant treatment
Introduction 
Atrial fibrillation (AF) is the most common 
sustained arrhythmia, with an estimated preva-
lence of 6 million among all Europeans [1]. The 
most serious complication of AF are throm-
boembolic events, especially embolic stroke. 
Patients with AF have a fivefold higher risk of 
stroke and a twofold higher risk of all-cause 
mortality than patients without AF [2]. The 
annual stroke risk varies from 0.19% to 23%, 
depending on patient risk factors (age, sex and 
co-morbidities) [3, 4]. Strokes in AF are as-
sociated with greater mortality and morbidity, 
more disability, longer hospital stays and lower 
rates of discharge to the patient’s home [5]. Ac-
cording to the Framingham Study, patients with 
a history of stroke due to AF have 25% and 63% 
risks of dying within 30 days and within 1 year, 
respectively [6]. Substantially high mortality 
and morbidity rates emphasize the need for 
a highly effective stroke prevention.
Anticoagulation therapy  
for stroke prevention 
Oral anticoagulant (OAC) agents are essential 
for the prevention of stroke and thromboembolism 
in AF patients. Two ways of anticoagulation are 
currently available — vitamin K antagonists (VKA) 
and non-vitamin K oral anticoagulants (NOAC). 
VKA therapy reduces the risk of stroke by 64% 
and mortality by 26%, as compared to aspirin or 
no therapy [7]. The use of VKA is limited by a nar-
row therapeutic interval, necessitating frequent 
monitoring and dose adjustments. It is estimated 
that only half of VKA-treated patients are within 
the therapeutic range of international normalized 
ratio (INR) [8]. The narrow therapeutic window of 
VKA leads to a delicate balance between a lack of 
efficacy and an increased risk of bleeding. NOAC, 
including the direct thrombin inhibitor dabigatran 
and factor Xa inhibitors apixaban, edoxaban and 
rivaroxaban, are increasingly used for stroke pre-
vention in patients with AF as alternatives to VKA. 
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Recently, four NOAC have been compared with 
warfarin in large randomized trials for the preven-
tion of stroke and systemic embolism. Both VKA 
and NOAC are effective in preventing stroke and 
systemic embolism in AF. A meta-analysis based 
on high-dose treatment groups of the main studies 
of warfarin vs. NOAC included 42,411 patients 
receiving NOAC and 29,272 receiving warfarin 
(71,683 participants included in the RE-LY, ROCK-
ET AF, ARISTOTLE, and ENGAGE AF-TIMI). 
NOAC at these doses significantly reduced the risk 
of stroke (RR 0.81; 95% CI 0.73–0.91; p < 0.0001), 
which was mainly due to a reduction in hemo-
rrhagic stroke (RR 0.49; 95% CI 0.38–0.64; 
p < 0.0001) and mortality (RR 0.90; 95% CI 
0.85–0.95; p = 0.0003), as compared to VKA. 
Intracranial hemorrhage was reduced by a half in 
patients randomized to the NOAC therapy (RR 
0.48; 95% CI 0.39–0.59; p = 0.0001), while gas-
trointestinal bleeding events were more frequent 
in comparison to the VKA therapy (RR 1.25; 95% 
CI 1.01–1.55; p = 0.04) [9].
According to current guidelines, oral antico-
agulation for prevention of stroke and systemic 
embolism are recommended in all male AF patients 
with a CHA2DS2-VASc score of 2 or more and in all 
female AF patients with a CHA2DS2-VASc score of 
3 or more. Oral anticoagulation for prevention of 
thromboembolism should be considered in male 
AF patients with a CHA2DS2-VASc score of 1 and 
in female AF patients with a CHA2DS2-VASc score 
of 2, considering individual characteristics and pa-
tient preferences [10]. When oral anticoagulation 
is initiated in a patient with non-valvular AF who 
is eligible for a NOAC, a NOAC is recommended 
in preference to a VKA.
Indication to left atrial  
appendage closure 
The presence of absolute contraindications to 
anticoagulant treatment is a major limitation in the 
use of NOAC or VKA. Contraindications exclude 
certain patients from any form of anticoagulation 
treatment, because the probability of bleeding in 
this group of AF patients is very high. On the other 
hand, discontinuation of anticoagulation treatment 
in patients with a high risk of stroke is not recom-
mended. For patients who are poor candidates for 
a long-term oral anticoagulation, percutaneous left 
atrial appendage occlusion (LAAO) is a device-
based alternative for stroke prophylaxis in AF. 
European guidelines for the management of AF 
now recommend that percutaneous LAA closure 
may be considered in patients with a high risk of 
stroke who have contraindications to long-term 
oral anticoagulation (class IIb indication, level of 
evidence B) [10]. According to the guidelines, pa-
tients after intracranial bleeding during anticoagu-
lant treatment are at a high risk of life-threatening 
bleeding. In this group of AF patients, LAAO may 
be considered (class IIb indication, level of evi-
dence B) [10].
Anatomy of left atrial appendage
Echocardiographic, surgical and autopsy 
studies suggest that LAA is a major source of 
thromboembolism in patients with AF and a site 
for thrombus formation in 90% of patients with 
thromboembolic events in non-valvular AF patients 
[11–12]. Transesophageal echocardiography (TEE) 
is the main imaging modality used to assess LAA 
anatomy, aid in the selection of a suitable device 
and size, and identify anatomic contraindications. 
Two-dimensional and three-dimensional TEE is 
used in conjunction with fluoroscopy to guide the 
procedure and evaluate device placement. LAA is 
the remnant of the original embryonic left atrium, 
a tubular, blind-ended pouch attached to the main 
body of the left atrium. LAA consist of three parts: 
ostium, neck and lobar region (Table 1) [13]. Based 
on computed tomography and cardiac magnetic res-
onance, the shapes of LAA were classified into four 
morphological types (Table 2) [13–16]. Important 
aspects that should be considered before LAAO are 
correct sizing of the landing zone diameters for the 
selected device and the measurement of the depth, 
number and origin of additional lobes. Lobes are 
defined as protrusions from the main body with the 
tail portion also representing a lobe. It is estimated 
that 80% of LAAs have a multilobed anatomy. 
Veinot et al. [17] found that the occurrence of 
2 (54%) lobes was most common, followed by 
3 (23%) lobes, 1 (20%) lobe and 4 (3%) lobes. It was 
noted that there were no significant differences in 
LAA morphologies attributed to sex or age. 
An increased number of lobes was associated 
with the presence of a thrombus independent of the 
clinical risk [18]. The “cauliflower” morphology is 
most often associated with embolic events. The 
risk of thrombus formation inside LAA during sinus 
rhythm and adequate blood flow is low. AF causes 
dysfunction and remodeling of LAA that predispose 
to low blood flow and thrombosis [19].
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Devices for percutaneous LAAO
Several devices have been proposed to achieve 
LAAO: PLAATO, WATCHMAN, Amplatzer Cardiac 
Plug, Amplatzer Cardiac Plug 2, Amplatzer Amulet, 
LARIAT, Wavecrest, Lambre, AtriClip Flex Device 
and Cardia Ultraseal. 
The first percutaneous LAA occluder was the 
Percutaneous Left Atrial Appendage Transcatheter 
Occlusion (PLAATO) device. Such devices repre-
sent a variety of designs and thus offer uniquely 
different approaches to the mechanical closure of 
LAA. The PLAATO system was designed as a self-
expanding nitinol cage covered with an expanded 
membrane to be delivered via a venous access and 
transseptal crossing into the left atrium. The first 
human percutaneous LAAO with the use of the 
PLAATO system was performed by Sievert and 
Lesh in 2001 [20]. The PLAATO device was with-
drawn from the market in 2006 despite favourable 
preliminary results in terms of safety and efficacy.
The second device developed was the WATCH-
MAN, which uses a semi-spherical nitinol frame 
partially coated with a polyethylene terephthalate 
membrane to block thrombus embolization while 
providing a scaffold over which endothelialization 
can occur. The fully repositionable device is avail-
able in five sizes, ranging from 21 mm to 33 mm, 
in order to accommodate varying LAA anatomies 
and sizes.
The Amplatzer Cardiac Plug (ACP) and the sec-
ond-generation ACP2 or Amplatzer Amulet involve 
similar implantation techniques. These devices 
consist of a nitinol mesh attached by a waist to an 
anchoring lobe surrounded by six stabilizing wires. 
The ACP is available in eight sizes allowing correct 
accommodation to individual LAA anatomies.
Table 1. Anatomy of left atrial appendage [13].
LAA region The ostium The neck The lobar region
Anatomic  
description
Opening from  
the LA to the LAA  
Diameter 10–40 mm 
Length 16–51 mm 
Volume 0.7–19.2 mL
The ostium opens to a neck  
region which constitutes  
a tubular junction between  
the ostium and the lobar region
Largest and most variable distal 
part of the LAA
Near structures Mitral value
Left upper pulmonary 
vein
Circumflex coronary artery
Left anterior descending artery
Sinus node artery (1/3)
The tip of the appendage  
overlaps the base of the  
pulmonary trunk, the left  
coronary artery, or its anterior 
branch and the great cardiac  
vein at varying levels
The left phrenic nerve runs  
along the pericardium  
overlaying the LAA
LA — left atrium; LAA — left atrium appendage
Table 2. Morphological classification left atrial appendage [13–16].
Type Chicken wing Cactus Windsock Cauliflower
Frequency  
of occurrences
48% 30% 19% 3%
Long of main lobe > 4 cm  
With a folded angle  
< 100 degrees
< 4 cm and > 2 
lobes of > 1 cm
> 4 cm with  
a folded angle  
> 100 degrees
< 4 cm without  
any forked lobes
Description Dominant lobe that 
presents with an 
obvious bend in its 
proximal or middle 
part, folding back  
on itself at some 
distance from  
the gap
Dominant central 
lobe and secondary 
lobes arise from it 
superiorly and  
inferiorly
Dominant lobe  
as the primary 
structure and there 
are variations in the 
location and number 
of secondary or 
even tertiary lobes
More complex internal 
characteristics, a varying 
number of lobes with 
lack of a dominant lobe, 
and a more irregular 
shape of the gap
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The LARIAT suture delivery device combines 
an epicardial and transcatheter endocardial ap-
proach. The LAA is entered using a transseptal 
approach and a magnetic tipped wire is placed at the 
tip of the LAA. A second magnetic wire is advanced 
through the pericardial space to the epicardial 
surface apposing the tip of the LAA. When the two 
magnetic wires are apposed, a suture can be guided 
over that rail and around the LAA. This device has 
a unique advantage in patients with paroxysmal 
AF, combining anatomical and electrophysiologi-
cal LAA ligation, excluding a potential source for 
AF initiation. 
The Cardia Ultraseal LAA closure device is 
a newly designed device that represents a novel 
approach to LAAO. The device is constructed with 
a nitinol frame to be soft and flexible. It is avail-
able in nine different bulb sizes (16–34 mm). This 
device has a unique next-generation design which 
combines the advantages of a distal anchoring bulb 
with the proven performance of a proximal sail to 
close the LAA orifice. These two components are 
connected with a dual articulating joint allowing the 
device to conform naturally to the most sinuous of 
LAA anatomies. 
Nowadays, three devices, WATCHMAN (the 
most widely investigated), Amplatzer Amulet, and 
ACP 1 are currently the most widely used occlud-
ers [16]. 
Efficacy of percutaneous LAAO  
in clinical study 
Since the first percutaneous LAAO in 2002 
many studies have investigated both safety and 
efficacy of this therapy using different closure 
devices. Only one device (WATCHMAN) has been 
compared with VKA therapy in randomized trials — 
PROTECT-AF (Watchman Left Atrial Appendage 
System for Embolic Protection in Patients With 
AF trial) and PREVAIL (Prospective Randomized 
Evaluation of the Watchman LAA Closure Device 
In Patients with AF Versus Long Term Warfarin 
Therapy trial). The PROTECT-AF trial was the first 
large randomized clinical trial to test this device 
[21]. The study evaluated 707 patients with non-
valvular AF who were randomly assigned at a 1:2 
ratio to either long-term warfarin with INR 2.0–3.0 
or the device therapy. The mean CHADS2 scores 
in the device and warfarin groups were 2.2 and 2.3, 
respectively. The device was placed successfully in 
91% patients. After a mean follow-up of 18 months 
(1.065 patient-years), the primary efficacy (stroke, 
systemic embolism and cardiovascular death) 
event rate was similar in both groups (3.0 vs. 4.9 
events per 100 patient-years). The PROTECT-AF 
study successfully demonstrated the non-inferi-
ority of the WATCHMAN device compared with 
standard warfarin therapy [21]. A sub-study of 
the PROTECT-AF study, assessing quality-of-
life parameters in 547 patients (361 device and 
186 warfarin patients) showed that patients who 
underwent LAAO had favourable changes in the 
quality of life at 12 months compared to patients 
treated with warfarin [22]. A post-hoc analysis of 
the PROTECT-AF and Continuous Access Protocol 
(CAP) registry assessed the net clinical benefit of 
LAAO, combining the rates of thromboembolism, 
intracranial hemorrhage, major adverse events 
and death for an objective comparison between 
LAA device closure vs. anticoagulation in patients 
with AF [24]. The long-term follow-up data of the 
PROTECT-AF trial were published in 2014. With 
a mean follow-up of 3.8 years or 2.621 patient-
years, the primary efficacy event rate (combined 
end-point of all strokes, cardiovascular or unex-
plained death and systemic embolism) was lower 
in the WATCHMAN group (2.3%) than in controls 
(3.8%), which is a 40% relative risk (RR) reduction, 
with a 96% posterior probability of superiority [24].
In the PREVAIL study, 407 patients with AF 
were randomly assigned at a 2:1 ratio either to 
undergo implantation of the WATCHMAN device 
or to continue conventional warfarin therapy alone. 
Due to a low rate of stroke in the control arm, 
PREVAIL did not achieve non-inferiority for its 
primary efficacy outcome [25].
Data on the effectiveness of LAAO for stroke 
prevention were confirmed in a patient-level 
meta-analysis of the two trials and their associated 
registries (PROTECT-AF, PREVAIL, CAP, CAP 2) 
[26]. This meta-analysis included 2,406 patients 
with 5,931 patient-years. With a mean follow-up 
of 2.69 years, patients receiving LAAO with the 
WATCHMAN device had significantly lower rates 
of hemorrhagic stroke (0.15 vs. 0.96 events/100 
patient-years; HR = 0.22; p < 0.004), cardiovas-
cular/unexplained death (1.1 vs. 2.3 events/100 
patient-years; HR = 0.48; p < 0.006) and non-
procedural bleeding (6.0% vs. 11.3%; HR = 0.51; 
p < 0.006) compared with warfarin. All-cause 
stroke or systemic embolism was similar in both 
groups (1.75 vs. 1.87 events/100 patient-years; 
HR = 1.02; 95% CI 0.62–1.7; p < 0.94). There 
were more ischemic strokes in the device group 
(1.6 vs. 0.9 and 0.2 vs. 1.0 events/100 patient-years; 
HR = 1.95 and 0.22, respectively; p < 0.05 and 
0.004, respectively) [26]. It should be noted that the 
LAAO therapy provides similar benefits as warfarin 
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for the composite efficacy endpoint of stroke, sys-
temic embolism or CV death. The pathophysiology 
of stroke was significantly different in both groups. 
More warfarin patients were experiencing hem-
orrhagic strokes and more device patients were 
experiencing ischemic strokes. Compared to the 
long-term warfarin therapy, patients randomized to 
LAAO have a significant improvement in survival, 
especially as regards CV death [26].
Sabiniewicz et al. [27] presented their first-in-
human original experience with the newly designed 
Cardia Ultraseal device. Six patients aged from 
64 to 70 years (mean 72.8 years) were selected 
for LAAO. The main indications for LAAO were 
gastrointestinal bleeding and nose bleeding. Mean 
HAS-BLED and CHA2DS2VASc scale was 3.8 for 
both. In 5 patients, the Cardia Ultraseal LAA de-
vice was implanted without any complications. In 
1 patient the anatomy of the LAA and surrounding 
structures was not suitable for device implantation 
and the procedure was discontinued. At a 1-month 
follow-up, the position of all devices on a TEE 
examination was optimal. There was no throm-
bus formation and no residual leak, and all LAAs 
were completely occluded [27]. The LAA closure 
may also be performed using surgical methods: 
intraoperative and thoracoscopic. Table 3 presents 
a review of the published data on percutaneous 
LAAO [21, 25, 28–35]. 
Safety of percutaneous LAAO
Left atrial appendage closure is a complicated 
procedure requiring the insertion of large catheters 
through the groin, transseptal puncture and cath-
eter navigation within both left atrium and LAA. 
Complications such as thrombus formation, bleed-
ing, stroke, vascular rupture, myocardial infarction 
and pericardial effusion may occur at each stage of 
the procedure. 
In the PROTECT-AF study, the most common 
safety endpoint in the intervention group was car-
diac tamponade requiring percutaneous or surgical 
drainage (4.8% patients). Other safety endpoints 
included periprocedural strokes (1.1%) and implant 
embolization (0.6%). Overall, major complications 
occurred in 6% of patients undergoing invasive 
treatment in the PROTECT-AF study [24]. Over 
the last months, the clinical data from the large 
real-world EWOLUTION registry with 1021 pa-
tients subsequent to WATCHMAN implantation 
have been published. Patients in this registry were 
at a high risk of stroke (average CHADS2 score: 2.8 
and a CHA2DS2VASc score: 4.5) but also had a mod-
erate-to-high risk of bleeding. Nearly one-third of 
all subjects had a history of major bleeding (31.2%). 
In 98.5% of patients, the device was successfully 
deployed with no flow or minimal residual flow 
(defined as < 5 mm assessed via periprocedural 
TEE) achieved in 99.3% of implanted patients. 
In this registry, the safety profile of the WATCH-
MAN device was more favorable, when compared 
to previous studies. Device or procedure-related 
serious adverse event rates on day 92 were similar 
in patients treated with warfarin or dual antiplatelet 
therapy (DAPT) (2.6% vs. 4.8%, respectively). 
The most common serious adverse event that oc-
curred within 30 days of the procedure was major 
bleeding requiring transfusion. In particular, the 
rate of procedural/device-related strokes, with 
a rate of 0.1% in that study, was substantially 
lower compared to the 0.9% in the PROTECT-AF 
and 0.4% in PREVAIL studies [36]. The success 
of the procedure significantly depends on the ex-
perience of the operator performing LAAO. This 
was confirmed in the PROTECT-AF study. The 
incidence of severe pericardial effusion was related 
to both centre and operator experience, being 50% 
higher in newly initiated sites. Moreover, the data 
derived from the CAP registry performed in the 
centres participating in the PROTECT-AF study 
after the study was closed, proved the cause-effect 
relationship between level of experience and risk 
of complication [37]. 
Anticoagulant/antiplatelet therapy  
after LAAO
The risk of thrombus formation on the sur-
face of devices implanted to eliminate the LAA is 
high, and it is necessary to use anticoagulant or 
antiplatelet therapy until the end epithelialization. 
Unfortunately, neither the type of therapy nor the 
duration of treatment has been clearly defined. In 
the PROTECT-AF study, patients allocated to the 
device group were treated post procedure with 
warfarin for 45 days to facilitate device endothe-
lialisation. Warfarin was discontinued if TEE at 
45 days after LAAO showed no complications. After 
discontinuation of warfarin, clopidogrel and aspirin 
were given over 6 months of follow-up. After this 
period, aspirin alone was continued. The control 
group received warfarin with INR 2.0–3.0, which 
was accomplished only over two-thirds of the time 
despite close INR monitoring [21]. It is important 
to remember that this study included patients 
with indications to anticoagulation treatment and 
no contraindications to anticoagulation treatment 
according to European Society of Cardiology (ESC) 
guidelines [10]. In the ASAP study, patients after 
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Table 3. Review of published data on percutaneous left atrial appendage occlusion. 
Device Trial Number  
of patients
Successful 
implant 
Outcomes Antithrombotic  
therapy after  
implantation
WATCHMAN PROTECT-AF 
[21]
707 90.9% Device group vs. VKA group:
•	 Ischemic CVA:  
9 (5.2%) vs. 6 (4.1%)
•	 Hemorrhagic stroke:  
3 (0.6%) vs. 10 (4.1%)
•	 Systemic embolization:  
3 (0.6%) vs. 0 (0%)
•	 All-cause mortality:  
57 (12.3%) vs. 44 (18%)
45 days of VKA  
followed by 4.5 months  
of clopidogrel and  
lifelong aspirin
PREVAIL [25] 407 95.1% Device group vs. VKA group:
•	 Ischemic CVA:  
5 (1.9%) vs. 1 (0.7%)
•	 Hemorrhagic stroke:  
1 (0.4%) vs. 0 (0%)
•	 Systemic embolization:  
1 (0.4%) vs. 0 (0%)
•	 Death (cardiac/unexplained): 
7 (2.6%) vs. 3 (2.2%)
45 days of VKA  
followed by 4.5 months  
of clopidogrel and  
lifelong aspirin
ASAP [28] 150 94.7% Ischemic CVA: 3 (1.7%) 
Hemorrhagic stroke: 1 (0.6%) 
All-cause mortality: 9 (5%)
45 days of VKA followed  
by 4.5 months of  
clopidogrel and lifelong 
aspirin
AMPLATZER Tzikas  
et al. [29]
1047 97.3% Stroke (type unspecified): 9% 
TIA: 9% 
Systemic embolism: 31 (2.3%) 
All-cause mortality: 63 (4.3%) 
Cardiac mortality: 17 (1.6%)
Aspirin/clopidogrel for  
1–3 months followed  
by ≥ 3 months aspirin
Kefer  
et al. [30]
90 98% Stroke (type unspecified):  
2 (2.2%) 
Myocardial infarction: 1 (1.1%) 
All-cause mortality: 4 (4.4%)
Aspirin/clopidogrel for  
1 month followed  
by lifelong aspirin
Urena  
et al. [31]
 
52 98.1% Stroke (1.7 years): 1.9%  
Systemic embolism: 
(1.7 years): 0% 
Aspirin plus clopidogrel,  
or aspirin or clopidogrel 
alone for 30–180 days  
followed by single  
antiplatelet therapy
ACP [32] 35 97.1% Stroke: 0 (0%)
Cardiac mortality: 0 (0%)
All-cause mortality: 3 (8.6%)
Aspirin/clopidogrel for  
3 months followed  
by aspirin for 6 months
LARIAT Price  
et al. [33]
154 94% Cardiac death: 2 (1.3%)
All-cause mortality: 3 (1.9%)
Stroke (unspecified type):  
2 (1.3%)
Aspirin: 47 (31%)
DAPT: 37 (24%)
No antithrombotic  
therapy: 29 (19%)
Clopidogrel: 11 (7%)
Bartus  
et al. [34]
89 96% Not available CHADS2 ≤ 1: aspirin
CHADS2 ≥ 2: VKA
Miller et al. 
[35]
41 93% Not available Aspirin: 19 (46%)
Clopidogrel: 3 (7%)
VKA: 8 (20%)
Dabigatran: 3 (7%)
Rivaroxaban: 1 (2%)
CVA — cerebrovascular accident; VKA — vitamin K antagonist; TIA — transient ischemic attack; DAPT — dual antiplatelet therapy
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WATCHMAN implantation were treated only 
with clopidogrel at a dose of 75 mg and aspirin at 
a dose of 75 mg over a 6 months period, and then 
only with aspirin [37]. The frequency of thrombus 
occurrence was comparable in patients in the 
ASAP study (4%) and in the PROTECT-AF study 
(4.2%) [21, 37]. In the EWOLUTION registry, 6% 
of patients following WATCHMAN implantation 
received no anticoagulation, 27% received oral 
anticoagulation (16% warfarin and 11% novel oral 
anticoagulants, NOAC), 60% received DAPT and 
7% of patients were on single antiplatelet therapy 
[36]. There were no indications of anticoagulant 
treatment following Amplatzer device implantation. 
The producer of the device recommended DAPT 
for 1 month and only aspirin for the next 5 months. 
According to ESC guidelines, after surgical occlu-
sion or exclusion of the LAA, it is recommended 
to continue anticoagulation for stroke prevention 
in high risk patients with AF [10].
Left atrial appendage occlusion:  
New perspectives, unresolved  
problems and gaps in evidence
The first 45 days after implantation of the 
device are a critical transition period, because 
after this time a complete endothelialization of the 
device is expected. An incomplete endothelializa-
tion, however, is associated with a risk of thrombus 
formation. According to the manufacturer’s recom-
mendation, warfarin is therefore recommended 
during the first 45 days after device implantation. 
There are data suggesting that DAPT is also rea-
sonable in patients with absolute contraindications 
to warfarin. New oral anticoagulants are increas-
ingly being used instead of warfarin. Data on the 
use of NOAC in patients after LAAO are scarce. 
A pilot study evaluated 45 patients after implanta-
tion of an LAA occlusion device (WATCHMAN) 
[38]. Following implantation, individualized drug 
therapy was instituted. Patients without prior 
DAPT or contraindications to OAC received NOAC 
(dabigatran or rivaroxaban) for ≥ 45 days accord-
ing to the operator’s decision. After 45 days, OAC 
was usually stopped and clopidogrel (75 mg/d.) 
and aspirin (100 mg/d.) was instituted for 6 months 
following WATCHMAN implantation. After that, 
clopidogrel was stopped and aspirin monotherapy 
was continued. After implantation, 27 (60%) pa-
tients received DAPT (aspirin 100 mg/d. and clopi-
dogrel 75 mg/d.) for ≥ 6 months and this scheme 
is now widely used after WATCHMAN implanta-
tion. Eighteen (40%) patients received NOAC. 
Dabigatran (2 × 110 mg/d.) was administered in 
16 patients and rivaroxaban (1 × 20 mg/d.) in 2 pa-
tients for ≥ 45 days. After this time, TEE revealed 
no abnormal thrombus formation.
During a follow-up of 417 ± 323 days, 7 pa-
tients died. No stroke or transient ischemic attack 
occurred. Non-fatal myocardial infarction occurred 
in 1 patient. There was a non-significant trend for 
a lower all-cause mortality (p = 0.159) and for the 
occurrence of major adverse cardiac and cerebro-
vascular events (p = 0.096) in the NOAC group, 
compared to the DAPT group. A total of 6 patients 
suffered from a major bleeding (NOAC group, n = 3; 
DAPT group, n = 3). There was no significant 
difference in the frequency of major bleeding be-
tween the groups. The presented study suggests 
that NOAC therapy within the first 45 days after 
WATCHMAN implantation was at least as safe and 
as effective as therapy with aspirin (100 mg/d.) 
and clopidogrel. There was no direct comparison 
between different ways of OAC, and especially be-
tween NOAC and warfarin in patients after LAAO. 
The presence of a thrombus in the LAA is 
considered as a contraindication to percutaneous 
LAAO, as manipulation of catheters, guidewires, 
sheaths or devices in the LAA may lead to systemic 
embolization. In patients with real contraindica-
tions to OAC, there is no alternative option for 
decreasing the high risk of an embolic event. The 
prevalence of LAA thrombi in patients with an 
LAAO indication is difficult to evaluate as LAA 
thrombi or dense spontaneous contrast on TEE 
are considered as exclusion criteria in the major-
ity of studies. There is no consensus for patients 
in whom a LAA thrombus is present and OAC is 
contraindicated.
An incomplete LAAO with peridevice leaks 
may allow thrombus embolization. Detection of 
peridevice leaks is challenging, and variable leak 
frequencies ranging from 8.2% to 62% have been 
reported after Amplatzer Cardiac Plug implanta-
tion on TEE or computed tomography imaging 
[39, 40]. Neuzner et al. [41] presented that the 
late decompression of the ACP lobe was observed 
in 61% of patients, leading to a complete loss in 
device compression in 27%. This observation may 
be the rationale for a higher degree of ACP oversiz-
ing during implantation. There are a few reports 
available showing an effective implantation of oc-
cluders in patients with thrombi in LAA. Aytemir 
et al. [42] described the first case of LAAO with 
the Amplatzer Amulet device in a patient who had 
a thrombus in LAA. The final result was excellent 
without a significant residual leak, pericardial effu-
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sion or embolic complications. Bokhari et al. [43] 
described the case of woman who was found to 
have LAA thrombus persistence despite dabigatran 
anticoagulation; she underwent LAA mechanical 
thrombectomy and subsequent successful LAAO 
with embolic neuroprotection. Meincke et al. [44] 
published two cases of successful LAAO using the 
WATCHMAN device and similar cerebral protec-
tion systems in patients with a known thrombus 
within LAA. Jalal et al. [45] published a case series 
of 3 patients known to have thrombi within LAA, 
in whom a successful percutaneous LAA closure 
was performed using a simplified implantation 
technique. No early procedural complications oc-
curred in these patients. It seems that LAAO may 
be alternative option for patients with LAA thrombi 
and contraindications to OAC. 
Despite several years of experience with dif-
ferent LAA closure systems, this form of stroke 
prevention in patients with AF and high risk of 
stroke has not become widely adopted. Issues 
which remain unresolved include a lack of data on 
optimal patient selection, risk of complications, and 
the possibility of incomplete LAA closure. Other 
important unresolved issues are the lack of recom-
mendations for the time of antiplatelet therapy, 
the lack of direct data comparing LAA occlusion 
with NOAC therapy and of data which compare 
devices, implanting strategies and therapies fol-
lowing implantation.
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